The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...

“These results show that inhibitory CARs have very interesting and underappreciated properties that can improve the performance of immune cell therapies,” said Wilson Wong, Ph.D., Professor of ...

The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.

March 17, 2026. Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data ...

Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of ...

Bio X Cell is the global leader of in vivo -ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed ...

The technology is designed to simplify the bio-separation process while reducing manufacturing costs.

Tevogen Bio files patent for T cell vaccine targeting entire viral genome, enhancing immune response against mutations and viral infections. Tevogen Bio, a clinical-stage immunotherapy biotech company ...

Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...